ERBB2 and neoplasm: There are preclinical studies suggesting that ADCs can achieve long-term anti-tumor immunity by promoting the generation of memory T cells, a phenomenon supported by some in vivo findings.D’Amico et al. used HER-2-targeted ADCs with anthracycline derivatives as potent loads to treat humanized HER-2-expressing (HER-2 +) homozygous mice.